BioProtein expands into recombinant vaccine production
BioProtein Technologies, the French biotechnology company specialising in the production of therapeutic proteins in the milk of transgenic rabbits, has extended its biomanufacturing services to include recombinant vaccine production.
BioProtein Technologies, the French biotechnology company specialising in the production of therapeutic proteins in the milk of transgenic rabbits, has extended its biomanufacturing services to include recombinant vaccine production.
Based on a novel technology platform developed in partnership with INRA, the French Agronomy Research Institute, using optimised Rotavirus Virus-Like Particles (Rotavirus-VLPs), BioProtein Technologies can produce recombinant vaccines.
The Rotavirus-VLPs will be used as antigen carriers to develop safe multivalent vaccines that will be produced in the milk of transgenic rabbits. This technology, for which INRA has filed a patent application allows the insertion of a wide range of antigenic molecules into the particles, from small peptides to large polypeptides carrying multiple epitopes. The technology will benefit pharmaceutical and biotechnology companies aiming to develop safe and effective vaccination approaches. It can be applied to a wide range of diseases such as life-threatening viral infections, including HIV, and cancers.
BioProtein Technologies has achieved production of Rotavirus-VLPs at expression and quality levels fully compatible with the industrial production of recombinant Rotavirus-VLP based vaccines.
'This is an important strategic achievement for BioProtein Technologies as it broadens our commercial offering in the area of recombinant biopharmaceutical production in the milk of transgenic rabbits,' said Marc Le Bozec, ceo of BioProtein Technologies. 'I am confident that the Rotavirus-VLPs platform will address the pharmaceutical and biotech industry's needs for safe and effective vaccines development.'